Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools Deans of Education

Pharmacogenomics Journal

Volumn 5, Issue 4, 2005, Pages 221-225

  Gurwitz, D ^a   Lunshof, J E ^b   Dedoussis, G ^c   Flordellis, C S ^d   Fuhr, U ^e   Kirchheiner, J ^e   Licinio, J ^f   Llerena, A ^g   Manolopoulos, V G ^h   Sheffield, L J ⁱ   Siest, G ^j   Torricelli, F ^k   Vasiliou, V ^l   Wong, S ^m  

^a TEL AVIV UNIVERSITY   (Israel)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HAROKOPIO UNIVERSITY   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF EXTREMADURA   (Spain)

^h DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j INSERM   (France)

^k CAREGGI UNIVERSITY HOSPITAL   (Italy)

^l UNIVERSITY OF COLORADO   (United States)

^m MEDICAL COLLEGE OF WISCONSIN   (United States)

more..

Author keywords

Adverse drug reactions (ADRs); Continuing medical education; Cytochrome P450 enzymes; Education; International Society of Pharmacogenetics (ISP); Personalized medicine; Pharmacogenetics; Thiopurine methyltransferase (TPMT)

Indexed keywords

APOLIPOPROTEIN E; BETA 2 ADRENERGIC RECEPTOR; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; DRUG; DRUG METABOLIZING ENZYME; THIOPURINE METHYLTRANSFERASE;

ARTICLE; DRUG EFFICACY; DRUG INDUSTRY; DRUG LABELING; DRUG LEGISLATION; DRUG SAFETY; EDUCATION PROGRAM; GENE EXPRESSION PROFILING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEALTH PRACTITIONER; HUMAN; HUMAN GENOME; LEGAL ASPECT; MEDICAL EDUCATION; MEDICAL ETHICS; MEDICAL PRACTICE; MEDICAL SCHOOL; MEDICAL SOCIETY; MEDICAL STUDENT; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE;

CURRICULUM; GUIDELINES; INTERNATIONAL COOPERATION; PHARMACOGENETICS; SCHOOLS, HEALTH OCCUPATIONS; SOCIETIES, MEDICAL;

EID: 23644449909     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500312     Document Type: Article

References (38)

1. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429: 464-468.
2. Meyer UA. Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004; 5: 669-676.
3. Siest G, Jeannesson E, Berrahmoune H, Maumus S, Marteau JB, Mohr S et al. Pharmacogenomics and drug response in cardiovascular disorders. Pharmacogenomics 2004; 5: 779-802.
4. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 2004; 3: 739-748.
5. Gurwitz D, Weizman A. Personalized psychiatry: a realistic goal. Pharmacogenomics 2004; 5: 213-217.
6. Frueh FW, Gurwitz D. From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics 2004; 5: 571-579.
7. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19.
8. Dormann H, Criegee-Rieck M, Neubert A, Egger T, Geise A, Krebs S et al. Lack of awareness of community-acquired adverse drug reactions upon hospital admission: dimensions and consequences of a dilemma. Drug Saf 2003; 26: 353-362.
9. Dormann H, Neubert A, Criegee-Rieck M, Egger T, Radespiel-Troger M, Azaz-Livshits T et al. Readmissions and adverse drug reactions in internal medicine: the economic impact. J Intern Med 2004; 255: 653-663.
10. Roche Press Release. First chip-based test for broad diagnostic use in European Union has CE mark. September 1, 2004. http://www.roche.com/med-cor-2004-09-01.
11. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72: 438-452.
12. Wuttke H, Rau T, Heide R, Bergmann K, Bohm M, Weil J et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002; 72: 429-437.
13. Kirchheiner J, Sasse J, Meineke I, Roots I, Brockmoller I. Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. Pharmacogenetics 2003; 13: 721-728.
14. Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002; 20: 2805-2811.
15. Langreth R, Waldholz M. New era of personalized medicine: targeting drugs for each unique genetic profile. Oncologist 1999; 4: 426-427.
16. Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 2001; 19: 491-496.
17. Rothstein MA, Epps PG. Ethical and legal implications of pharmacogenomics. Nat Rev Genet 2001; 2: 228-231.
18. Moldrup C. Ethical, social and legal implications of pharmacogenomics: a critical review. Community Genet 2001; 4: 204-214.
19. Lipton P. Pharmacogenetics: the ethical issues. Pharmacogenomics J 2003; 3: 14-16.
20. Wertz DC. Ethical, social and legal issues in pharmacogenomics. Pharmacogenomics J 2003; 3: 194-196.
21. Winkelmann BR. Pharmacogenomics, genetic testing and ethnic variability: tackling the ethical questions. Pharmacogenomics 2003; 4: 531-535.
22. Weijer C, Miller PB. Protecting communities in pharmacogenetic and pharmacogenomic research. Pharmacogenomics J 2004; 4: 9-16.
23. van Delden J, Bolt I, Kalis A, Derijks J, Leufkens H. Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics. Bioethics 2004; 18: 303-321.
24. Webster A, Martin P, Lewis G, Smart A. Integrating pharmacogenetics into society: in search of a model. Nat Rev Genet 2004; 5: 663-669.
25. Breckenridge A, Lindpaintner K, Lipton P, McLeod H, Rothstein M, Wallace H. Pharmacogenetics: ethical problems and solutions. Nat Rev Genet 2004; 5: 676-680.
26. Nuffield Council on Bioethics. Pharmacogenetics: ethical issues. 2003. http://www.nuffieldbioethics.org/fileLibrary/pdf/ pharmacog_consultation.pdf
27. European Commission 2004. Ethical, legal and social aspects of genetic testing: research, development and clinical applications. European Commission Expert Group. http://europa.eu.int/comm/research/-conferences/2004/genetic/pdf/ report_en.pdf
28. Vizirianakis IS. Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine. Eur J Pharm Sci 2002; 15: 243-250.
29. Brock TP, Faulkner CM, Williams DM, Smith SR. Continuing-education programs in pharmacogenomics for pharmacists. Am J Health Syst Pharm 2002; 59: 722-725.
30. McCurdy CR. Pharmacy education: from Prescott to pharmacogenomics. J Am Pharm Assoc (Wash) 2002; 42: 688-691.
31. Sansgiry SS. The future of pharmacy education: back to which basics? Pharmacotherapy 2004; 24: 688-989.
32. Gurwitz D, Weizman A, Rehavi M. Education: teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol Sci 2003; 24: 122-125.
33. Watson RT, Suter E, Romrell LJ, Harman EM, Rooks LG, Neims AH. Moving a graveyard: how one school prepared the way for continuous curriculum renewal. Acad Med 1998; 73: 948-955.
34. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173-192.
35. Kohn L, Corrigan J, Donaldson M (eds). To Err is Human. Building a Safer Health System. Committee on Quality of Health Care in America. Institute of Medicine. National Academy Press: Washington, DC, 1999. http://books.nap.edu/html/to_err_is_human/.
36. Auxter-Parham S. Bringing pharmacogenomic assays to market. Clin Lab News 2004; 30: 1-7.
37. Nebert DW, Jorge-Nebert L, Vesell ES. Pharmacogenomics and 'individualized drug therapy': high expectations and disappointing achievements. Am J Pharmacogenomics 2003; 3: 361-370.
38. Pirazzoli A, Recchia G. Pharmacogenetics and pharmacogenomics: are they still promising? Pharmacol Res 2004; 49: 357-361.